Buscar
Mostrando ítems 1-10 de 11
Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals
(MDPI, 2021-06-12)
With the spread of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a need to assess the protection conferred by both previous infections and current vaccination. ...
SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity
(Nature Research, 2021-01-28)
The protective effect of neutralizing antibodies in SARS-CoV-2 infected individuals is not yet well defined. To address this issue, we have analyzed the kinetics of neutralizing antibody responses and ...
Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
(Cell Press, 2022-01-24)
To understand the determinants of long-term immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the concurrent impact of vaccination and emerging variants, we follow a ...
Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals
(Cell Press, 2022-10-28)
Mass vaccination campaigns reduced COVID-19 incidence and severity. Here, we evaluated the immune responses developed in SARS-CoV-2-uninfected patients with predominantly antibody-deficiencies (PAD) ...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and humoral responses against different variants of concern in domestic pet animals and stray cats from North-Eastern Spain
(Wiley, 2022-09-27)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19) pandemic in humans, is able to infect several domestic, captive and wildlife ...
First Detection of SARS-CoV-2 Delta (B.1.617.2) Variant of Concern in a Dog with Clinical Signs in Spain
(MDPI, 2021-12-16)
Several cases of naturally infected dogs with severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) have been reported despite the apparently low susceptibility of this species. Here, we
document ...
Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant
(Frontiers Media, 2023-12-04)
Most COVID-19 vaccines are based on the SARS-CoV-2 Spike glycoprotein (S) or
their subunits. However, S shows some structural instability that limits its
immunogenicity and production, hampering the ...
Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
(Elsevier, 2021-01-31)
Background. Understanding mid-term kinetics of immunity to SARS-CoV-2 is the cornerstone for public health control of the pandemic and vaccine development. However, current evidence is rather based on ...
A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity
(Nature Research, 2024-02-05)
Here we report the characterization of 17T2, a SARS-CoV-2 pan-neutralizing
human monoclonal antibody isolated from a COVID-19 convalescent individual infected during the first pandemic wave. 17T2 is a ...
Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models
(Nature Research, 2024-02-27)
AgeisassociatedwithreducedefficacyofvaccinesandlinkedtohigherriskofsevereCOVID-19.Herewe
determined the impact of ageing on the efficacy of a SARS-CoV-2 vaccine based on a stabilised Spike
glycoprotein ...